1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Apellis Has New Hope for Pegcetacoplan With Longer-Term Data

18-Month Results Could Vindicate Geographic Atrophy Program

 
• By Alaric DeArment

One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.

Eye
Apellis announced longer-term data for pegcetacoplan in geographic atrophy • Source: Shutterstock

Apellis Pharmaceuticals, Inc. bolstered its chances of success for its intravitreal pegcetacoplan in geographic atrophy with Phase III follow-up data that vindicated a study previously viewed as a failure.

Apellis said on 16 March that in longer-term data from the Phase III DERBY and OAKS studies, pegcetacoplan had continued to reduce lesion growth and demonstrate a favorable safety profile at month 18 in patients with geographic atrophy secondary to age-related macular degeneration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.